Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

被引：23

作者：

Petty, Amy J. ^{[1
]}

Heyman, Benjamin ^{[2
]}

Yang, Yiping ^{[3
]}

机构：

[1] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA

[2] Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92093 USA

[3] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

来源：

CANCERS | 2020年 / 12卷 / 04期

基金：

美国国家卫生研究院;

关键词：

CAR-T cells; CAR-NK cells; CAR-NKT cells; cancer immunotherapy; solid tumors; hematologic malignancies; genetic engineering; novel approaches; CAR-T-CELLS; NATURAL-KILLER-CELLS; IN-VIVO EXPANSION; B-CELL; ADOPTIVE IMMUNOTHERAPY; 4-1BB COSTIMULATION; CD19; LYMPHOMA; ACTIVATION; NEUROTOXICITY;

D O I：

10.3390/cancers12040842

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptors (CAR) are fusion proteins engineered from antigen recognition, signaling, and costimulatory domains that can be used to reprogram T cells to specifically target tumor cells expressing specific antigens. Current CAR-T cell technology utilizes the patient's own T cells to stably express CARs and has achieved exciting clinical success in the past few years. However, current CAR-T cell therapy still faces several challenges, including suboptimal persistence and potency, impaired trafficking to solid tumors, local immunosuppression within the tumor microenvironment and intrinsic toxicity associated with CAR-T cells. This review focuses on recent strategies to improve the clinical efficacy of CAR-T cell therapy and other exciting CAR approaches currently under investigation, including CAR natural killer (NK) and NKT cell therapies.

引用

页数：17

共 110 条

[81] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma [J].

Raje, Noopur ;

Berdeja, Jesus ;

Lin, Yi ;

Siegel, David ;

Jagannath, Sundar ;

Madduri, Deepu ;

Liedtke, Michaela ;

Rosenblatt, Jacalyn ;

Maus, Marcela V. ;

Turka, Ashley ;

Lam, Lyh-Ping ;

Morgan, Richard A. ;

Friedman, Kevin ;

Massaro, Monica ;

Wang, Julie ;

Russotti, Greg ;

Yang, Zhihong ;

Campbell, Timothy ;

Hege, Kristen ;

Petrocca, Fabio ;

Quigley, M. Travis ;

Munshi, Nikhil ;

Kochenderfer, James N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (18) :1726-1737

[82] Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition [J].

Ren, Jiangtao ;

Liu, Xiaojun ;

Fang, Chongyun ;

Jiang, Shuguang ;

June, Carl H. ;

Zhao, Yangbing .

CLINICAL CANCER RESEARCH, 2017, 23 (09) :2255-2266

[83] Engineering Natural Killer Cells for Cancer Immunotherapy [J].

Rezvani, Katayoun ;

Rouce, Rayne ;

Liu, Enli ;

Shpall, Elizabeth .

MOLECULAR THERAPY, 2017, 25 (08) :1769-1781

[84] Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies [J].

Rodgers, David T. ;

Mazagova, Magdalena ;

Hampton, Eric N. ;

Cao, Yu ;

Ramadoss, Nitya S. ;

Hardy, Ian R. ;

Schulman, Andrew ;

Du, Juanjuan ;

Wang, Feng ;

Singer, Oded ;

Ma, Jennifer ;

Nunez, Vanessa ;

Shen, Jiayin ;

Woods, Ashley K. ;

Wright, Timothy M. ;

Schultz, Peter G. ;

Kim, Chan Hyuk ;

Young, Travis S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (04) :E459-E468

[85] Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting [J].

Rotolo, Antonia ;

Caputo, Valentina S. ;

Holubova, Monika ;

Baxan, Nicoleta ;

Dubois, Olivier ;

Chaudhry, Mohammed Suhail ;

Xiao, Xiaolin ;

Goudevenou, Katerina ;

Pitcher, David S. ;

Petevi, Kyriaki ;

Kachramanoglou, Carolina ;

Iles, Sandra ;

Naresh, Kikkeri ;

Maher, John ;

Karadimitris, Anastasios .

CANCER CELL, 2018, 34 (04) :596-+

[86] CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells [J].

Rupp, Levi J. ;

Schumann, Kathrin ;

Roybal, Kole T. ;

Gate, Rachel E. ;

Ye, Chun J. ;

Lim, Wendell A. ;

Marson, Alexander .

SCIENTIFIC REPORTS, 2017, 7

[87] The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering [J].

Sackstein, Robert .

FRONTIERS IN IMMUNOLOGY, 2019, 9

[88] EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss [J].

Sampson, John H. ;

Choi, Bryan D. ;

Sanchez-Perez, Luis ;

Suryadevara, Carter M. ;

Snyder, David J. ;

Flores, Catherine T. ;

Schmittling, Robert J. ;

Nair, Smita K. ;

Reap, Elizabeth A. ;

Norberg, Pamela K. ;

Herndon, James E., II ;

Kuan, Chien-Tsun ;

Morgan, Richard A. ;

Rosenberg, Steven A. ;

Johnson, Laura A. .

CLINICAL CANCER RESEARCH, 2014, 20 (04) :972-984

[89] Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia [J].

Santomasso, Bianca D. ;

Park, Jae H. ;

Salloum, Darin ;

Riviere, Isabelle ;

Flynn, Jessica ;

Mead, Elena ;

Halton, Elizabeth ;

Wang, Xiuyan ;

Senechal, Brigitte ;

Purdon, Terence ;

Cross, Justin R. ;

Liu, Hui ;

Vachha, Behroze ;

Chen, Xi ;

DeAngelis, Lisa M. ;

Li, Daniel ;

Bernal, Yvette ;

Gonen, Mithat ;

Wendel, Hans-Guido ;

Sadelain, Michel ;

Brentjens, Renier J. .

CANCER DISCOVERY, 2018, 8 (08) :958-971

[90] CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients [J].

Savoldo, Barbara ;

Ramos, Carlos Almeida ;

Liu, Enli ;

Mims, Martha P. ;

Keating, Michael J. ;

Carrum, George ;

Kamble, Rammurti T. ;

Bollard, Catherine M. ;

Gee, Adrian P. ;

Mei, Zhuyong ;

Liu, Hao ;

Grilley, Bambi ;

Rooney, Cliona M. ;

Heslop, Helen E. ;

Brenner, Malcolm K. ;

Dotti, Gianpietro .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (05) :1822-1826

← 2 3 4 5 6 7 8 9 10 11 →